Reporting bias in drug trials submitted to the Food and Drug Administration: review of publication and presentation.
<h4>Background</h4>Previous studies of drug trials submitted to regulatory authorities have documented selective reporting of both entire trials and favorable results. The objective of this study is to determine the publication rate of efficacy trials submitted to the Food and Drug Admin...
Guardado en:
Autores principales: | Kristin Rising, Peter Bacchetti, Lisa Bero |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2008
|
Materias: | |
Acceso en línea: | https://doaj.org/article/28965d5679dd481ba2ca126fb757c080 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration.
por: Irving Kirsch, et al.
Publicado: (2008) -
Characteristics and conflicts of interest at Food and Drug Administration Gastrointestinal Drug Advisory Committee meetings.
por: Rishad Khan, et al.
Publicado: (2021) -
Screening and Identification of Lujo Virus Entry Inhibitors From an Food and Drug Administration-Approved Drugs Library
por: Junyuan Cao, et al.
Publicado: (2021) -
Bilateral implantation of +3.0 D multifocal toric intraocular lenses: results of a US Food and Drug Administration clinical trial
por: Lehmann R, et al.
Publicado: (2017) -
Assessment of pancreatitis associated with tocilizumab use using the United States Food and Drug Administration Adverse Event Reporting System database
por: Ashwin Kamath, et al.
Publicado: (2021)